Compare Illumina, Inc. (ILMN) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Vanguard Total World Stock Index Fund ETF — how do they compare? Illumina, Inc. trades at $193.06 (market cap $28.96B), while Vanguard Total World Stock Index Fund ETF trades at $161.08. Which is the better fit depends on your goals.
| ILMN | VT | |
|---|---|---|
Market Cap | $28.96B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $205.10 | $161.30 |
52-Week Low | $91.00 | $132.19 |
Enterprise Value | $30.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
Vanguard Total World Stock ETF (VT) trades at $161.3, up 0.86% on the day, with a bullish technical signal driven by moving averages. The ETF offers broad global diversification across over 10,000 stocks with a low 0.06% expense ratio. Recent institutional activity shows mixed positioning adjustments, while news highlights its role in global portfolios amid trade policy uncertainty.
VT presents a long-term diversification opportunity with low-cost global equity exposure, though near-term risks include trade war volatility and seasonal choppiness. The neutral oscillator signals and high short-term RSI suggest potential consolidation, but strong institutional interest supports its core holding appeal for risk-conscious investors seeking worldwide market access.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
